Tenax Therapeutics (TENX) Accumulated Expenses (2011 - 2026)
Tenax Therapeutics recorded quarterly Accumulated Expenses of $2.1 million in Q1 2026, up 91.93% quarter-over-quarter from $1.1 million in Q4 2025, and up 130.36% year-over-year from $929000.0 in Q1 2025.
Tenax Therapeutics' Accumulated Expenses history runs 16 years deep, the most recent figure standing at $2.1 million for Q1 2026.
- In Q1 2026, Accumulated Expenses rose 130.36% year-over-year to $2.1 million; the TTM figure through Mar 2026 stood at $2.1 million (up 130.36% YoY), while the FY2025 annual figure was $1.1 million, down 27.41% from the prior year.
- Accumulated Expenses came in at $2.1 million for Q1 2026 at Tenax Therapeutics, up from $1.1 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $2.1 million in Q1 2026 to a low of $41633.0 in Q2 2023.
- A 5-year average of $816440.9 and a median of $775045.0 in 2022 frame the typical range for Accumulated Expenses.
- Across the five-year window, Accumulated Expenses tumbled 90.42% in 2023 and soared 1961.64% in 2024, its largest moves.
- Tenax Therapeutics' Accumulated Expenses stood at $775045.0 in 2022, then surged by 30.7% to $1.0 million in 2023, then jumped by 51.63% to $1.5 million in 2024, then decreased by 27.41% to $1.1 million in 2025, then surged by 91.93% to $2.1 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $2.1 million, $1.1 million, and $991000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Tenax Therapeutics | 542.72 Mn | 542.72 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.14 Mn |
| Dec 31, 2025 | 1.12 Mn |
| Sep 30, 2025 | 991,000.00 |
| Jun 30, 2025 | 1.97 Mn |
| Mar 31, 2025 | 929,000.00 |
| Dec 31, 2024 | 1.54 Mn |
| Sep 30, 2024 | 977,545.00 |
| Jun 30, 2024 | 431,798.00 |
| Mar 31, 2024 | 536,443.00 |
| Dec 31, 2023 | 1.01 Mn |
| Sep 30, 2023 | 47,416.00 |
| Jun 30, 2023 | 41,633.00 |
| Mar 31, 2023 | 61,156.00 |
| Dec 31, 2022 | 775,045.00 |
| Sep 30, 2022 | 424,415.00 |
| Jun 30, 2022 | 434,539.00 |
| Mar 31, 2022 | 460,506.00 |
| Dec 31, 2021 | 704,340.00 |
| Sep 30, 2021 | 685,114.00 |
| Jun 30, 2021 | 127,551.00 |
| Mar 31, 2021 | 222,780.00 |
| Dec 31, 2020 | 860,629.00 |
| Sep 30, 2020 | 295,451.00 |
| Jun 30, 2020 | 121,592.00 |
| Mar 31, 2020 | 699,525.00 |
| Dec 31, 2019 | 333,873.00 |
| Sep 30, 2019 | 903,512.00 |
| Jun 30, 2019 | 489,265.00 |
| Mar 31, 2019 | 75,054.00 |
| Dec 31, 2018 | 815,855.00 |
| Sep 30, 2018 | 104,300.00 |
| Jun 30, 2018 | 565,087.00 |
| Mar 31, 2018 | 100,781.00 |
| Dec 31, 2017 | 363,306.00 |
| Sep 30, 2017 | 223,088.00 |
| Jun 30, 2017 | 1.68 Mn |
| Mar 31, 2017 | 69,627.00 |
| Dec 31, 2016 | 5.25 Mn |
| Sep 30, 2016 | 3.35 Mn |
| Jun 30, 2016 | 3.39 Mn |
| Mar 31, 2016 | 3.83 Mn |
| Dec 31, 2015 | 545,715.00 |
| Apr 30, 2015 | 596,137.00 |
| Jan 31, 2015 | 46,393.00 |
| Oct 31, 2014 | 1.30 Mn |
| Jul 31, 2014 | 612,822.00 |
| Apr 30, 2014 | 858,136.00 |
| Jan 31, 2014 | 1.49 Mn |
| Oct 31, 2013 | 322,443.00 |
| Jul 31, 2013 | 95,051.00 |
| Apr 30, 2013 | 66,632.00 |
| Jan 31, 2013 | 1.09 Mn |
| Oct 31, 2012 | 428,817.00 |
| Jul 31, 2012 | 1.11 Mn |
| Apr 30, 2012 | 1.27 Mn |
| Jan 31, 2012 | 1.14 Mn |
| Oct 31, 2011 | 1.31 Mn |
| Jul 31, 2011 | 1.19 Mn |
| Apr 30, 2011 | 1.25 Mn |